Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975347 · ClinicalTrials.gov registry record · Phase 1
Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank
A Phase 1 study of Reproductive Disorders, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT04975347 is a Phase 1 study of Reproductive Disorders that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 47 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04975347, a Phase 1 study of Reproductive Disorders, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in healthy subjects.
Conditions Studied
Interventions
- DRUG Naloxone
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2025-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975347
The ClinicalTrials.gov registry entry for NCT04975347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Reproductive Disorders appearing as the primary indexed condition, and to 1 intervention - of which Naloxone is the first listed.
NCT04975347 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04975347 about?
NCT04975347 is a clinical study titled "Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank". The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in healthy subjects.
What is the current status of trial NCT04975347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2022-06-03. Estimated completion is 2025-08-08.
What conditions does trial NCT04975347 study?
This clinical trial studies the following conditions: Reproductive Disorders.
What interventions are being tested in trial NCT04975347?
The interventions under investigation include: Naloxone (DRUG).
Who is sponsoring clinical trial NCT04975347?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975347 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.